These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22804226)

  • 1. Systematic development of pH-independent controlled release tablets of carvedilol using central composite design and artificial neural networks.
    Aktas E; Eroglu H; Kockan U; Oner L
    Drug Dev Ind Pharm; 2013 Aug; 39(8):1207-16. PubMed ID: 22804226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on formulation development of mouth dissolving tablets of Carvedilol.
    Pokharkar V; Dhar S; Mandpe L
    Hindustan Antibiot Bull; 2007 Feb-2008 Nov; 49-50(1-4):21-8. PubMed ID: 19957540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation development of carvedilol compression coated tablet.
    Shah R; Patel S; Patel H; Pandey S; Shah S; Shah D
    Pharm Dev Technol; 2013; 18(4):906-15. PubMed ID: 21797662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ternary complexation of carvedilol, beta-cyclodextrin and citric acid for mouth-dissolving tablet formulation.
    Pokharkar V; Khanna A; Venkatpurwar V; Dhar S; Mandpe L
    Acta Pharm; 2009 Jun; 59(2):121-32. PubMed ID: 19564138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of carvedilol transdermal patches: evaluation of physicochemical, ex vivo and mechanical properties.
    Gannu R; Vishnu YV; Kishan V; Rao YM
    PDA J Pharm Sci Technol; 2008; 62(6):391-401. PubMed ID: 19634343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH sensitive alginate-chitosan hydrogel beads for carvedilol delivery.
    Meng X; Li P; Wei Q; Zhang HX
    Pharm Dev Technol; 2011 Feb; 16(1):22-8. PubMed ID: 20028209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tracking of crystalline-amorphous transition of carvedilol in rotary spun microfibers and their formulation to orodispersible tablets for in vitro dissolution enhancement.
    Szabó P; Sebe I; Stiedl B; Kállai-Szabó B; Zelkó R
    J Pharm Biomed Anal; 2015 Nov; 115():359-67. PubMed ID: 26280924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and in vitro characterization of non-effervescent floating drug delivery system of poorly soluble drug, carvedilol phosphate.
    Srikanth Meka V; Wee Liang VA; Dharmalingham SR; Sheshala R; Gorajana A
    Acta Pharm; 2014 Dec; 64(4):485-94. PubMed ID: 25531788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of a drug delivery system with bimodal pH dependent release of a poorly soluble drug.
    Kovacic B; Vrecer F; Planinsek O
    Pharmazie; 2011 Jun; 66(6):465-6. PubMed ID: 21699090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and in vivo evaluation of carvedilol buccal mucoadhesive patches.
    Thimmasetty J; Pandey G; Babu P
    Pak J Pharm Sci; 2008 Jul; 21(3):241-8. PubMed ID: 18614419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial neural networks in the modeling and optimization of aspirin extended release tablets with Eudragit L 100 as matrix substance.
    Ibrić S; Jovanović M; Djurić Z; Parojcić J; Petrović SD; Solomun L; Stupar B
    AAPS PharmSciTech; 2003; 4(1):E9. PubMed ID: 12916918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery.
    Akhgari A; Afrasiabi Garekani H; Sadeghi F; Azimaie M
    Int J Pharm; 2005 Nov; 305(1-2):22-30. PubMed ID: 16236475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits.
    Aljimaee YH; El-Helw AR; Ahmed OA; El-Say KM
    Drug Des Devel Ther; 2015; 9():1379-92. PubMed ID: 25834396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artificial neural networks in the optimization of a nimodipine controlled release tablet formulation.
    Barmpalexis P; Kanaze FI; Kachrimanis K; Georgarakis E
    Eur J Pharm Biopharm; 2010 Feb; 74(2):316-23. PubMed ID: 19815063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with Gelucire 50/13.
    Potluri RH; Bandari S; Jukanti R; Veerareddy PR
    Arch Pharm Res; 2011 Jan; 34(1):51-7. PubMed ID: 21468915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of matrix tablets controlled drug release using Elman dynamic neural networks and decision trees.
    Petrović J; Ibrić S; Betz G; Đurić Z
    Int J Pharm; 2012 May; 428(1-2):57-67. PubMed ID: 22402474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of drug release by utilizing pH-independent matrix system comprising water soluble drug verapamil hydrochloride.
    Baviskar D; Sharma R; Jain D
    Pak J Pharm Sci; 2013 Jan; 26(1):137-44. PubMed ID: 23261739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucoadhesive bilayer buccal tablet of carvedilol-loaded chitosan microspheres: in vitro, pharmacokinetic and pharmacodynamic investigations.
    Yedurkar P; Dhiman MK; Petkar K; Sawant K
    J Microencapsul; 2012; 29(2):126-37. PubMed ID: 22047549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and characterization of enteric microparticles by coacervation.
    Thomas S; Chong YN; Chaw CS
    Drug Dev Ind Pharm; 2013 Jul; 39(7):1142-51. PubMed ID: 23003201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An improvement in physicochemical properties of carvedilol through spherically agglomerated solid dispersions with PVP K30.
    Tapas A; Kawtikwar P; Sakarkar D
    Acta Pol Pharm; 2012; 69(2):299-308. PubMed ID: 22568045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.